{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T08:01:58Z","timestamp":1693987318390},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5-6","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Provectus Biopharmaceuticals"},{"name":"Delcath Systems"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10585-018-9890-1","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T02:32:01Z","timestamp":1525746721000},"page":"495-502","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Regional therapies for locoregionally advanced and unresectable melanoma"],"prefix":"10.1007","volume":"35","author":[{"given":"Evan S.","family":"Weitman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"issue":"9460","key":"9890_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(05)17951-3","volume":"365","author":"JF Thompson","year":"2005","unstructured":"Thompson JF, Scolyer RA, Kefford RF (2005) Cutaneous melanoma. Lancet 365(9460):687\u2013701. https:\/\/doi.org\/10.1016\/S0140-6736(05)17951-3","journal-title":"Lancet"},{"issue":"1","key":"9890_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21387","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"9890_CR3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF, for members of the American Joint Committee on Cancer Melanoma Expert Panel, the International Melanoma Database, Discovery Platform (2017) Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 67(6):472\u2013492. https:\/\/doi.org\/10.3322\/caac.21409","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"9890_CR4","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1245\/s10434-012-2469-1","volume":"19","author":"D Han","year":"2012","unstructured":"Han D, Yu D, Zhao X, Marzban SS, Messina JL, Gonzalez RJ, Cruse CW, Sarnaik AA, Puleo C, Sondak VK, Zager JS (2012) Sentinel node biopsy is indicated for thin melanomas \u2265 0.76 mm. Ann Surg Oncol 19(11):3335\u20133342. https:\/\/doi.org\/10.1245\/s10434-012-2469-1","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"9890_CR5","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","volume":"148","author":"O Creech Jr","year":"1958","unstructured":"Creech O Jr, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148(4):616\u2013632","journal-title":"Ann Surg"},{"issue":"9","key":"9890_CR6","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/1097-0142(196709)20:9<1351::AID-CNCR2820200902>3.0.CO;2-#","volume":"20","author":"R Cavaliere","year":"1967","unstructured":"Cavaliere R, Ciocatto EC, Giovanella BC, Heidelberger C, Johnson RO, Margottini M, Mondovi B, Moricca G, Rossi-Fanelli A (1967) Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 20(9):1351\u20131381","journal-title":"Cancer"},{"issue":"3","key":"9890_CR7","first-page":"339","volume":"140","author":"JS Stehlin","year":"1975","unstructured":"Stehlin JS, Giovanella BC, de Ipolyi PD, Muenz LR, Anderson RF (1975) Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 140(3):339\u2013348","journal-title":"Surg Gynecol Obstet"},{"issue":"11","key":"9890_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0011-3840(99)80008-2","volume":"36","author":"DL Fraker","year":"1999","unstructured":"Fraker DL (1999) Hyperthermic regional perfusion for melanoma and sarcoma of the limbs. Curr Probl Surg 36(11):841\u2013907","journal-title":"Curr Probl Surg"},{"issue":"3","key":"9890_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11864-004-0009-3","volume":"5","author":"DL Fraker","year":"2004","unstructured":"Fraker DL (2004) Management of in-transit melanoma of the extremity with isolated limb perfusion. Curr Treat Options Oncol 5(3):173\u2013184","journal-title":"Curr Treat Options Oncol"},{"issue":"11","key":"9890_CR10","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/archsurg.139.11.1237","volume":"139","author":"EM Noorda","year":"2004","unstructured":"Noorda EM, Vrouenraets BC, Nieweg OE, van Geel BN, Eggermont AM, Kroon BB (2004) Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 139(11):1237\u20131242. https:\/\/doi.org\/10.1001\/archsurg.139.11.1237","journal-title":"Arch Surg"},{"issue":"4","key":"9890_CR11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/jso.10077","volume":"79","author":"BB Kroon","year":"2002","unstructured":"Kroon BB, Noorda EM, Vrouenraets BC, Nieweg OE (2002) Isolated limb perfusion for melanoma. J Surg Oncol 79(4):252\u2013255. https:\/\/doi.org\/10.1002\/jso.10077","journal-title":"J Surg Oncol"},{"issue":"6","key":"9890_CR12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1097\/00000658-199612000-00011","volume":"224","author":"AM Eggermont","year":"1996","unstructured":"Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC, Lejeune FJ (1996) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224(6):756\u2013764 (discussion 764\u2013755)","journal-title":"Ann Surg"},{"issue":"25","key":"9890_CR13","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1200\/JCO.2005.05.5152","volume":"24","author":"WR Cornett","year":"2006","unstructured":"Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, Sussman JJ, Kraybill WG, Kane JM 3rd, Alexander HR, Lee JE, Mansfield PF, Pingpank JF, Winchester DJ, White RL Jr, Chadaram V, Herndon JE 2nd, Fraker DL, Tyler DS, American College of Surgeons Oncology Group Trial Z (2006) Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24(25):4196\u20134201. https:\/\/doi.org\/10.1200\/JCO.2005.05.5152","journal-title":"J Clin Oncol"},{"issue":"3","key":"9890_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/02656730701805520","volume":"24","author":"MG Moller","year":"2008","unstructured":"Moller MG, Lewis JM, Dessureault S, Zager JS (2008) Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperth 24(3):275\u2013289. https:\/\/doi.org\/10.1080\/02656730701805520","journal-title":"Int J Hyperth"},{"issue":"3","key":"9890_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<238::AID-SSU8>3.0.CO;2-9","volume":"14","author":"JF Thompson","year":"1998","unstructured":"Thompson JF, Kam PC, Waugh RC, Harman CR (1998) Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14(3):238\u2013247","journal-title":"Semin Surg Oncol"},{"issue":"8","key":"9890_CR16","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1245\/s10434-008-9988-9","volume":"15","author":"GM Beasley","year":"2008","unstructured":"Beasley GM, Petersen RP, Yoo J, McMahon N, Aloia T, Petros W, Sanders G, Cheng TY, Pruitt SK, Seigler H, Tyler DS (2008) Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 15(8):2195\u20132205. https:\/\/doi.org\/10.1245\/s10434-008-9988-9","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"9890_CR17","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1517\/17425250903559881","volume":"6","author":"AA Santillan","year":"2010","unstructured":"Santillan AA, Zager JS (2010) Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US. Expert Opin Drug Metab Toxicol 6(9):1033\u20131037. https:\/\/doi.org\/10.1517\/17425250903559881","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"9890_CR18","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1245\/s10434-012-2782-8","volume":"20","author":"J Wong","year":"2013","unstructured":"Wong J, Chen YA, Fisher KJ, Zager JS (2013) Isolated limb infusion in a series of over 100 infusions: a single-center experience. Ann Surg Oncol 20(4):1121\u20131127. https:\/\/doi.org\/10.1245\/s10434-012-2782-8","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"9890_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","volume":"18","author":"J Wieberdink","year":"1982","unstructured":"Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 18(10):905\u2013910","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"5","key":"9890_CR20","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jamcollsurg.2008.12.019","volume":"208","author":"GM Beasley","year":"2009","unstructured":"Beasley GM, Caudle A, Petersen RP, McMahon NS, Padussis J, Mosca PJ, Zager JS, Hochwald SN, Grobmyer SR, Delman KA, Andtbacka RH, Noyes RD, Kane JM, Seigler H, Pruitt SK, Ross MI, Tyler DS (2009) A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 208(5):706\u2013715. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2008.12.019 (discussion 715\u2013707)","journal-title":"J Am Coll Surg"},{"issue":"13","key":"9890_CR21","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1245\/s10434-017-6107-9","volume":"24","author":"C O\u2019Donoghue","year":"2017","unstructured":"O\u2019Donoghue C, Perez MC, Mullinax JE, Hardman D, Sileno S, Naqvi SMH, Kim Y, Gonzalez RJ, Zager JS (2017) Isolated limb infusion: a single-center experience with over 200 infusions. Ann Surg Oncol 24(13):3842\u20133849. https:\/\/doi.org\/10.1245\/s10434-017-6107-9","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"9890_CR22","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1245\/s10434-017-6046-5","volume":"24","author":"HM Kroon","year":"2017","unstructured":"Kroon HM, Coventry BJ, Giles MH, Henderson MA, Speakman D, Wall M, Barbour A, Serpell J, Paddle P, Smithers BM, Thompson JF (2017) Safety and efficacy of isolated limb infusion chemotherapy for advanced locoregional melanoma in elderly patients: an Australian multicenter study. Ann Surg Oncol 24(11):3245\u20133251. https:\/\/doi.org\/10.1245\/s10434-017-6046-5","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"9890_CR23","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","volume":"23","author":"MS Hughes","year":"2016","unstructured":"Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B, Choi J, McCluskey K, Whitman E, Agarwala S, Siskin G, Nutting C, Toomey MA, Webb C, Beresnev T, Pingpank JF (2016) Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol 23(4):1309\u20131319. https:\/\/doi.org\/10.1245\/s10434-015-4968-3","journal-title":"Ann Surg Oncol"},{"key":"9890_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000356","author":"AM Abbott","year":"2017","unstructured":"Abbott AM, Doepker MP, Kim Y, Perez MC, Gandle C, Thomas KL, Choi J, Shridhar R, Zager JS (2017) Hepatic progression-free and overall survival after regional therapy to the liver for metastatic melanoma. Am J Clin Oncol. https:\/\/doi.org\/10.1097\/COC.0000000000000356","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"9890_CR25","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1245\/ASO.2004.07.004","volume":"11","author":"ED Feldman","year":"2004","unstructured":"Feldman ED, Pingpank JF, Alexander HR Jr (2004) Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 11(3):290\u2013297","journal-title":"Ann Surg Oncol"},{"key":"9890_CR26","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.2147\/OPTH.S28863","volume":"7","author":"PR Pereira","year":"2013","unstructured":"Pereira PR, Odashiro AN, Lim LA, Miyamoto C, Blanco PL, Odashiro M, Maloney S, De Souza DF, Burnier MN Jr (2013) Current and emerging treatment options for uveal melanoma. Clin Ophthalmol 7:1669\u20131682. https:\/\/doi.org\/10.2147\/OPTH.S28863","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"9890_CR27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/jso.23501","volume":"109","author":"MR Forster","year":"2014","unstructured":"Forster MR, Rashid OM, Perez MC, Choi J, Chaudhry T, Zager JS (2014) Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol 109(5):434\u2013439. https:\/\/doi.org\/10.1002\/jso.23501","journal-title":"J Surg Oncol"},{"issue":"10","key":"9890_CR28","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1517\/17425255.2014.951330","volume":"10","author":"OM Rashid","year":"2014","unstructured":"Rashid OM, Sloot S, Zager JS (2014) Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol 10(10):1355\u20131364. https:\/\/doi.org\/10.1517\/17425255.2014.951330","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"9890_CR29","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.ejso.2009.02.016","volume":"35","author":"P Mariani","year":"2009","unstructured":"Mariani P, Piperno-Neumann S, Servois V, Berry MG, Dorval T, Plancher C, Couturier J, Levy-Gabriel C, Lumbroso-Le Rouic L, Desjardins L, Salmon RJ (2009) Surgical management of liver metastases from uveal melanoma: 16 years\u2019 experience at the Institut Curie. Eur J Surg Oncol 35(11):1192\u20131197. https:\/\/doi.org\/10.1016\/j.ejso.2009.02.016","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"9890_CR30","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1001\/archopht.123.12.1639","volume":"123","author":"M Diener-West","year":"2005","unstructured":"Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Straatsma BR, Thoma J, Collaborative Ocular Melanoma Study Group (2005) Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report no. 26. Arch Ophthalmol 123(12):1639\u20131643. https:\/\/doi.org\/10.1001\/archopht.123.12.1639","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"9890_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0161-6420(91)32285-1","volume":"98","author":"ES Gragoudas","year":"1991","unstructured":"Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, Munzenrider JE, Spar MD (1991) Survival of patients with metastases from uveal melanoma. Ophthalmology 98(3):383\u2013389 (discussion 390)","journal-title":"Ophthalmology"},{"issue":"1","key":"9890_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ohc.2004.07.003","volume":"18","author":"AD Singh","year":"2005","unstructured":"Singh AD, Borden EC (2005) Metastatic uveal melanoma. Ophthalmol Clin North Am 18(1):143\u2013150. https:\/\/doi.org\/10.1016\/j.ohc.2004.07.003","journal-title":"Ophthalmol Clin North Am"},{"key":"9890_CR33","unstructured":"Coley WB (1991) The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res (262):3\u201311"},{"issue":"4","key":"9890_CR34","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/00000658-197410000-00029","volume":"180","author":"DL Morton","year":"1974","unstructured":"Morton DL, Eilber FR, Holmes EC, Hunt JS, Ketcham AS, Silverstein MJ, Sparks FC (1974) BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg 180(4):635\u2013643","journal-title":"Ann Surg"},{"issue":"8","key":"9890_CR35","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/cncr.20166","volume":"100","author":"SS Agarwala","year":"2004","unstructured":"Agarwala SS, Neuberg D, Park Y, Kirkwood JM (2004) Mature results of a phase III randomized trial of bacillus Calmette\u2013Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I\u2013III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 100(8):1692\u20131698. https:\/\/doi.org\/10.1002\/cncr.20166","journal-title":"Cancer"},{"issue":"8","key":"9890_CR36","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.1128\/JVI.71.8.6049-6054.1997","volume":"71","author":"B He","year":"1997","unstructured":"He B, Chou J, Brandimarti R, Mohr I, Gluzman Y, Roizman B (1997) Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 71(8):6049\u20136054","journal-title":"J Virol"},{"issue":"4","key":"9890_CR37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, McGrath Y, Thomas SK, Thornton M, Bullock P, Love CA, Coffin RS (2003) ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10(4):292\u2013303. https:\/\/doi.org\/10.1038\/sj.gt.3301885","journal-title":"Gene Ther"},{"issue":"34","key":"9890_CR38","doi-asserted-by":"publisher","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","volume":"27","author":"NN Senzer","year":"2009","unstructured":"Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ (2009) Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27(34):5763\u20135771. https:\/\/doi.org\/10.1200\/JCO.2009.24.3675","journal-title":"J Clin Oncol"},{"issue":"22","key":"9890_CR39","doi-asserted-by":"publisher","first-page":"6737","DOI":"10.1158\/1078-0432.CCR-06-0759","volume":"12","author":"JC Hu","year":"2006","unstructured":"Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, Harrington KJ, James ND, Love CA, McNeish I, Medley LC, Michael A, Nutting CM, Pandha HS, Shorrock CA, Simpson J, Steiner J, Steven NM, Wright D, Coombes RC (2006) A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12(22):6737\u20136747. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-0759","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9890_CR40","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2217\/imt.15.35","volume":"7","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Puzanov I, Kelley MC (2015) Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy 7(6):611\u2013619. https:\/\/doi.org\/10.2217\/imt.15.35","journal-title":"Immunotherapy"},{"issue":"25","key":"9890_CR41","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH Jr, Zager JS, Ye Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS (2015) Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780\u20132788. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377","journal-title":"J Clin Oncol"},{"issue":"13","key":"9890_CR42","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","volume":"23","author":"RH Andtbacka","year":"2016","unstructured":"Andtbacka RH, Ross M, Puzanov I, Milhem M, Collichio F, Delman KA, Amatruda T, Zager JS, Cranmer L, Hsueh E, Chen L, Shilkrut M, Kaufman HL (2016) Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial. Ann Surg Oncol 23(13):4169\u20134177. https:\/\/doi.org\/10.1245\/s10434-016-5286-0","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"9890_CR43","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/CMR.0b013e32831328c7","volume":"18","author":"JF Thompson","year":"2008","unstructured":"Thompson JF, Hersey P, Wachter E (2008) Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 18(6):405\u2013411. https:\/\/doi.org\/10.1097\/CMR.0b013e32831328c7","journal-title":"Melanoma Res"},{"issue":"1","key":"9890_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/CMR.0b013e328331caa2","volume":"20","author":"MC Foote","year":"2010","unstructured":"Foote MC, Burmeister BH, Thomas J, Mark Smithers B (2010) A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series. Melanoma Res 20(1):48\u201351. https:\/\/doi.org\/10.1097\/CMR.0b013e328331caa2","journal-title":"Melanoma Res"},{"issue":"7","key":"9890_CR45","doi-asserted-by":"publisher","first-page":"e68561","DOI":"10.1371\/journal.pone.0068561","volume":"8","author":"P Toomey","year":"2013","unstructured":"Toomey P, Kodumudi K, Weber A, Kuhn L, Moore E, Sarnaik AA, Pilon-Thomas S (2013) Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS ONE 8(7):e68561. https:\/\/doi.org\/10.1371\/journal.pone.0068561","journal-title":"PLoS ONE"},{"issue":"7","key":"9890_CR46","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","volume":"22","author":"JF Thompson","year":"2015","unstructured":"Thompson JF, Agarwala SS, Smithers BM, Ross MI, Scoggins CR, Coventry BJ, Neuhaus SJ, Minor DR, Singer JM, Wachter EA (2015) Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol 22(7):2135\u20132142. https:\/\/doi.org\/10.1245\/s10434-014-4169-5","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"9890_CR47","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","volume":"170","author":"A Ribas","year":"2017","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV (2017) Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170(6):1109\u20131119. https:\/\/doi.org\/10.1016\/j.cell.2017.08.027","journal-title":"Cell"},{"issue":"6","key":"9890_CR48","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00262-017-1967-1","volume":"66","author":"R Dummer","year":"2017","unstructured":"Dummer R, Hoeller C, Gruter IP, Michielin O (2017) Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. Cancer Immunol Immunother 66(6):683\u2013695. https:\/\/doi.org\/10.1007\/s00262-017-1967-1","journal-title":"Cancer Immunol Immunother"},{"issue":"10105","key":"9890_CR49","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank C, Petrella TM, Hamid O, Zhou H, Ebbinghaus S, Ibrahim N, Robert C (2017) Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390(10105):1853\u20131862. https:\/\/doi.org\/10.1016\/S0140-6736(17)31601-X","journal-title":"Lancet"},{"issue":"22","key":"9890_CR50","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1200\/JCO.2016.67.1529","volume":"34","author":"I Puzanov","year":"2016","unstructured":"Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, Chastain M, Gorski KS, Anderson A, Chou J, Kaufman HL, Andtbacka RH (2016) Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol 34(22):2619\u20132626. https:\/\/doi.org\/10.1200\/JCO.2016.67.1529","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"9890_CR51","doi-asserted-by":"publisher","first-page":"Abstract 9568","DOI":"10.1200\/JCO.2016.34.15_suppl.9568","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV (2016) Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pe,bro) for unresectable stage IIIB-IV melanoma. J Clin Oncol 34(suppl):Abstract 9568","journal-title":"J Clin Oncol"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-018-9890-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-018-9890-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-018-9890-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T18:00:14Z","timestamp":1604253614000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-018-9890-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":51,"journal-issue":{"issue":"5-6","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["9890"],"URL":"https:\/\/doi.org\/10.1007\/s10585-018-9890-1","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"17 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}